Research programme: BRD9 protein degradation therapeutics - Amphista Therapeutics
Alternative Names: BRD9-protein-degradersLatest Information Update: 06 Jun 2024
At a glance
- Originator Amphista Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action BRD9 protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer